SOCS2 overexpression alleviates diabetic nephropathy in rats by inhibiting the TLR4/NF-κB pathway. 2017

Suxia Yang, and Junwei Zhang, and Shiying Wang, and Xinxin Zhao, and Jun Shi
Department of Nephrology, Huaihe Hospital of Henan University, Kaifeng, 475000, China.

Suppressor of cytokine signaling 2 (SOCS2) was reported to be involved in the development of Diabetic Nephropathy (DN). However, its underlying mechanism remains undefined. Western blot was carried out to determine the expressions of SOCS2, Toll-like receptors 4 (TLR4) and nuclear factor kappa B (NF-κB) pathway-related proteins in DN patients, streptozotocin (STZ)-induced DN rats and high glucose (HG)-stimulated podocytes. The effects of SOCS2 overexpression on renal injury, the inflammatory cytokines production, renal pathological changes, apoptosis and the TLR4/NF-κB pathway in DN rats or HG-stimulated podocytes were investigated. TLR4 antagonist TAK-242 and NF-κB inhibitor PDTC were used to confirm the functional mechanism of SOCS2 overexpression in HG-stimulated podocytes. SOCS2 was down-regulated, while TLR4 and NF-κB were up-regulated in renal tissues of DN patients and DN rats. Ad-SOCS2 infection alleviated STZ-induced renal injury and pathological changes and inhibited STZ-induced IL-6, IL-1β and MCP-1 generation and activation of the TLR4/NF-κB pathway in DN rats. SOCS2 overexpression attenuated apoptosis, suppressed the inflammatory cytokines expression, and inactivated the TLR4/NF-κB pathway in HG-stimulated podocytes. Suppression of the TLR4/NF-κB pathway enhanced the inhibitory effect of SOCS2 overexpression on apoptosis and inflammatory cytokines expressions in HG-stimulated podocytes. SOCS2 overexpression alleviated the development of DN by inhibiting the TLR4/NF-κB pathway, contributing to developing new therapeutic strategies against DN.

UI MeSH Term Description Entries

Related Publications

Suxia Yang, and Junwei Zhang, and Shiying Wang, and Xinxin Zhao, and Jun Shi
March 2018, Biological research,
Suxia Yang, and Junwei Zhang, and Shiying Wang, and Xinxin Zhao, and Jun Shi
September 2020, Journal of food biochemistry,
Suxia Yang, and Junwei Zhang, and Shiying Wang, and Xinxin Zhao, and Jun Shi
January 2022, Clinical and experimental pharmacology & physiology,
Suxia Yang, and Junwei Zhang, and Shiying Wang, and Xinxin Zhao, and Jun Shi
October 2019, European review for medical and pharmacological sciences,
Suxia Yang, and Junwei Zhang, and Shiying Wang, and Xinxin Zhao, and Jun Shi
May 2020, Immunobiology,
Suxia Yang, and Junwei Zhang, and Shiying Wang, and Xinxin Zhao, and Jun Shi
October 2018, Bioscience reports,
Suxia Yang, and Junwei Zhang, and Shiying Wang, and Xinxin Zhao, and Jun Shi
December 2021, Pharmaceutical biology,
Suxia Yang, and Junwei Zhang, and Shiying Wang, and Xinxin Zhao, and Jun Shi
August 2023, Cellular signalling,
Suxia Yang, and Junwei Zhang, and Shiying Wang, and Xinxin Zhao, and Jun Shi
October 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
Suxia Yang, and Junwei Zhang, and Shiying Wang, and Xinxin Zhao, and Jun Shi
May 2024, Nephrology (Carlton, Vic.),
Copied contents to your clipboard!